WallStreetZenWallStreetZen

NASDAQ: BIOR
Biora Therapeutics Inc Stock

$1.17+0.01 (+0.86%)
Updated Dec 8, 2023
BIOR Price
$1.17
Fair Value Price
$3.95
Market Cap
$27.73M
52 Week Low
$1.05
52 Week High
$7.68
P/E
-0.12x
P/B
-0.23x
P/S
1,811.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.00k
Earnings
-$122.42M
Gross Margin
100%
Operating Margin
-619,444.44%
Profit Margin
-680,133.3%
Debt to Equity
-1.29
Operating Cash Flow
-$46M
Beta
1.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BIOR Overview

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIOR ($1.17) is undervalued by 70.36% relative to our estimate of its Fair Value price of $3.95 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIOR ($1.17) is significantly undervalued by 70.36% relative to our estimate of its Fair Value price of $3.95 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BIOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOR due diligence checks available for Premium users.

Be the first to know about important BIOR news, forecast changes, insider trades & much more!

Valuation

BIOR fair value

Fair Value of BIOR stock based on Discounted Cash Flow (DCF)
Price
$1.17
Fair Value
$3.95
Undervalued by
70.36%
BIOR ($1.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOR ($1.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BIOR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.12x
Industry
11.7x
Market
31.32x

BIOR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.23x
Industry
5.42x

BIOR's financial health

Profit margin

Revenue
$0.0
Net Income
-$73.5M
Profit Margin
0%
BIOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BIOR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$34.7M
Liabilities
$153.5M
Debt to equity
-1.29
BIOR's short-term liabilities ($69.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOR's long-term liabilities ($83.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$11.0M
Investing
-$1.0k
Financing
-$2.8M
BIOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BIOR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BIOR$27.73M+0.86%-0.12x-0.23x
FRLN$27.72M0.00%-0.56x0.92x
UBX$27.63M-0.53%-0.59x0.76x
NRXP$27.86M+0.61%-0.66x-4.48x
FBIO$27.90M-5.45%0.72x1.67x

Biora Therapeutics Stock FAQ

What is Biora Therapeutics's quote symbol?

(NASDAQ: BIOR) Biora Therapeutics trades on the NASDAQ under the ticker symbol BIOR. Biora Therapeutics stock quotes can also be displayed as NASDAQ: BIOR.

If you're new to stock investing, here's how to buy Biora Therapeutics stock.

What is the 52 week high and low for Biora Therapeutics (NASDAQ: BIOR)?

(NASDAQ: BIOR) Biora Therapeutics's 52-week high was $7.68, and its 52-week low was $1.05. It is currently -84.77% from its 52-week high and 11.43% from its 52-week low.

How much is Biora Therapeutics stock worth today?

(NASDAQ: BIOR) Biora Therapeutics currently has 23,703,672 outstanding shares. With Biora Therapeutics stock trading at $1.17 per share, the total value of Biora Therapeutics stock (market capitalization) is $27.73M.

Biora Therapeutics stock was originally listed at a price of $328.00 in Jun 19, 2020. If you had invested in Biora Therapeutics stock at $328.00, your return over the last 3 years would have been -99.64%, for an annualized return of -84.72% (not including any dividends or dividend reinvestments).

How much is Biora Therapeutics's stock price per share?

(NASDAQ: BIOR) Biora Therapeutics stock price per share is $1.17 today (as of Dec 8, 2023).

What is Biora Therapeutics's Market Cap?

(NASDAQ: BIOR) Biora Therapeutics's market cap is $27.73M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biora Therapeutics's market cap is calculated by multiplying BIOR's current stock price of $1.17 by BIOR's total outstanding shares of 23,703,672.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.